AA
BBH icon

Ascent Advisors’s VanEck Biotech ETF BBH Stock Holding History

Ascent Advisors’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,450
Closed -$2.68M – 56
2026
Q1 		$2.68M Buy
+59,450
New +$11.5M 4.92% 7

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ascent Advisors's BBH Position: Q2 2026 in Review

Ascent Advisors sold out of VanEck Biotech ETF (BBH) in Q2 2026, closing a stake of 59,450 shares — an estimated $2.68M sold.

Ascent Advisors first reported a position in BBH in Q1 2026 and held it in 1 quarter. The position peaked at $2.68M in Q1 2026. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Ascent Advisors reported no remaining VanEck Biotech ETF position as of Q2 2026 after selling out during the quarter.
  • Ascent Advisors sold 59,450 VanEck Biotech ETF shares in Q2 2026, an estimated $2.68M.
  • Ascent Advisors first reported a position in VanEck Biotech ETF in Q1 2026 and held it in 1 quarter.
  • Ascent Advisors's VanEck Biotech ETF position peaked at $2.68M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Ascent Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.